ACM
RNAC icon

Asymmetry Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Asymmetry Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,845
Closed -$137K – 42
2020
Q3 		$137K Buy
+1,845
New +$141K 0.09% 34

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Asymmetry Capital Management's RNAC Position: Q4 2020 in Review

Asymmetry Capital Management sold out of Cartesian Therapeutics (RNAC) in Q4 2020, closing a stake of 1,845 shares — an estimated $137K sold.

Asymmetry Capital Management first reported a position in RNAC in Q3 2020 and held it in 1 quarter. The position peaked at $137K in Q3 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q4 2020.

  • Asymmetry Capital Management reported no remaining Cartesian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 1,845 Cartesian Therapeutics shares in Q4 2020, an estimated $137K.
  • Asymmetry Capital Management first reported a position in Cartesian Therapeutics in Q3 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's Cartesian Therapeutics position peaked at $137K in Q3 2020.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2020.

Based on Asymmetry Capital Management's 13F filing for Q4 2020, filed 11 Feb 2021.